OS Therapies (NYSE:OSTX) Shares Up 5.1% – Here’s Why

OS Therapies Inc (NYSE:OSTX) traded up 5.1% during mid-day trading on Friday . The company traded as high as $2.06 and last traded at $1.95. 20,692 shares changed hands during trading, a decline of 85% from the average session volume of 133,760 shares. The stock had previously closed at $1.86.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OSTX. Brookline Capital Management upgraded shares of OS Therapies to a “strong-buy” rating in a research report on Thursday, August 22nd. EF Hutton Acquisition Co. I raised shares of OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd.

OS Therapies Trading Up 5.1 %

The company has a 50-day simple moving average of $2.84.

Institutional Trading of OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC purchased a new stake in OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.